Led by 83North, This Round of Financing Brings Total Funding to Over $100 Million

TEL AVIV, Israel, Sept. 6, 2023 — Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced it has closed a $55 million Series C financing round led by 83North. Additional participants in the round were Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital. The financing brings total funding to over $100 million since Ibex’s inception in 2016.

Ibex is transforming cancer diagnostics with AI-powered solutions that help pathologists improve the quality of diagnosis and support laboratories with enhanced efficiency and better turnaround times. Cancer incidence is rising around the world while its diagnosis becomes more complex and nuanced, causing heavy workloads for pathologists and laboratories. The increasing demand is compounded by a global shortage of pathologists who still rely heavily on manual work and solely on visual analysis of biopsies. Ibex’s Galen platform helps overcome these challenges with AI-powered workflows and decision support tools that pathologists use in their everyday practice.

“Ibex is leading the market in live customer deployments as we remain steadfast in our mission of providing every patient with a timely, accurate and personalized cancer diagnosis,” said Joseph Mossel, Co-Founder and CEO of Ibex. “This latest financing round will enable us to take major steps toward reaching our goal. We will be using the funds to expand our footprint in the United States to meet the increasing demand for AI-powered diagnostic solutions, and to accelerate the growth of our product portfolio to create more tools for pathologists and labs as they digitally transform their practices. This financing round highlights our strong commercial momentum and our tenacity in pursuing the opportunities that lie ahead.”

Ibex’s Galen platform is the most widely deployed AI technology in pathology and has been deployed in laboratories and pathology departments around the world. Ibex achieved several significant milestones recently, including live deployment of Galen at University of Pittsburgh Medical Center (UPMC), the completion of national roll out throughout Wales, and collaboration with AstraZeneca and Daiichi Sankyo for the development of an AI-powered biomarker scoring product for breast cancer. Galen provides health systems and diagnostic laboratories with an integrated solution for cancer diagnosis and biomarker scoring, capable of detecting more the 100 different cancer and non-cancer pathologies while offering enhanced interoperability with scanning systems, image management solutions and lab information systems. Ibex was recently showcased in a KLAS Research report which provided consistently favorable feedback from global customers.

“Our continued investment in Ibex is a testament to the company’s progress in recent years, bringing its unparalleled technology to laboratories, hospitals and digital pathology networks worldwide, catapulting the industry into an AI-powered era,” added Gil Goren, Partner at 83North and Board Director of Ibex. “Ibex’s successful deployments demonstrate its responsiveness to market and customer needs, while its product portfolio continues to grow and meet new market demands. We are eager to see Ibex forge the way with new uses of AI in cancer diagnosis, supporting providers as they work to improve patient care and outcomes.”

About Ibex Medical Analytics

Ibex Medical Analytics (Ibex) is transforming cancer diagnostics with world-leading, clinical grade AI-powered solutions, empowering physicians to provide accurate, timely and personalized cancer diagnosis for every patient. Our Galen™ suite of solutions is the first and most widely deployed AI-technology in pathology and is used as part of everyday routine, supporting pathologists and providers worldwide in improving the quality and accuracy of diagnosis, implementing comprehensive quality control, reducing turnaround times and boosting productivity with more efficient workflows. Ibex’s Artificial Intelligence technology is built on Deep Learning algorithms trained by a team of pathologists, data scientists and software engineers. For additional company information, please visit https://ibex-ai.com/ and follow us on LinkedIn and Twitter.     

The Galen™ platform includes certain solutions which are CE marked and registered with the UK MHRA. The solutions are for Research Use Only (RUO) in the United States and not cleared by the FDA. For more information, including indication for use and regulatory approval in other countries, contact Ibex Medical Analytics.

Media Contacts

Ibex Medical Analytics
Nechama Rosengarten
FINN Partners
Nechama.rosengarten@finnpartners.com  
+1 929 588 2009    

Logo – https://mma.prnewswire.com/media/1839936/Ibex_Logo.jpg

SOURCE Ibex Medical Analytics

Streamlined Ventures led recent round of $3.5 million of new investment to further accelerate development of the Antaris Cloud Platform

LOS ALTOS, Calif., Sept. 6, 2023 — Antaris, the software platform for space, announced the company has closed a preferred seed funding round of $3.5 million, led by California-based Streamlined Ventures. In conjunction with its initial seed and seed extension rounds, Antaris has now raised nearly $10 million, significantly exceeding original seed-stage investment targets. Ullas Naik, Founder and General Partner of Streamlined Ventures, has joined the Antaris Board of Directors.

“Our investors have been tremendous champions of Antaris at every step of the way,” said Tom Barton, Co-Founder and CEO of Antaris. “The addition of Streamlined Ventures to our strong investor base will help us to accelerate the next stage of our growth, and we welcome Ullas to our Board of Directors.”

“This is an incredibly exciting time for the space ecosystem,” noted Ullas Naik, Founder and General Partner of Streamlined Ventures. “Antaris is the first company we’ve seen that is committed to building a pure-play software and SaaS company to support satellites and space data networking. This platform is game-changing for anyone looking to put a satellite into orbit or to operate satellite constellations.”

The round also includes additional investment from existing insiders—including venture capital firms HCVC, E2MC and Antaris founders. The company’s first seed round and a recent seed extension were completed in partnership with existing investors Acequia Capital, HCVC, Possible Ventures, Lockheed Martin Ventures, E2MC and Ananth Technologies.

Antaris was recently awarded a contract to support the US Department of Defense and is preparing to launch its second technology demonstration satellite, JANUS-2, in the coming months.

About Antaris
Antaris, the software platform for space, is on a mission to make space open, accessible and scalable. We dramatically simplify the design, simulation and operation of satellites, giving customers the flexibility and security to deliver mission success at a fraction of typical costs. Learn more at www.antaris.space

SOURCE Antaris

De financiering zal ViAqua de mogelijkheid bieden om zijn eerste product op de markt te brengen, te investeren in R&D voor toekomstige producten en het vermogen van het platform te bewijzen om op RNA gebaseerde oplossingen op schaal te leveren.

HAIFA, Israël, 5 september 2023 — ViAqua Therapeutics, een biotechnologiebedrijf en ontwikkelaar van een platform voor oraal toegediende RNA-deeltjes ter bevordering en verbetering van de diergezondheid in de aquacultuur, heeft bekendgemaakt de financieringsronde van USD 8,25 miljoen te hebben afgerond onder leiding van S2G Ventures en met deelname van Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels en Circle Investments LLC.

Aquacultuur is essentieel voor het verbeteren van de voedselzekerheid, het bieden van een gezonde en duurzame voedselbron en het beschermen van wilde visbestanden in het licht van de groeiende vraag naar mariene eiwitten. Maar volgens een analyse van Kontali is ziektebeheer op dit moment het grootste probleem waarmee de aquacultuursector te maken heeft, met een economische impact van meer dan USD 8,5 miljard voor alleen al de garnalenindustrie.

Om dit probleem aan te pakken heeft ViAqua een op biotechnologie gebaseerd platform voor orale toediening ontwikkeld voor het gericht toedienen van op RNA gebaseerde oplossingen om de ziekteresistentie in de aquacultuur te verbeteren.

“Oraal toedienen is de heilige graal van de gezondheidsontwikkeling in de aquacultuur, omdat het onmogelijk is om garnalen individueel te vaccineren, maar ook de operationele kosten van ziektebeheer substantieel te verlagen en tegelijkertijd de resultaten te verbeteren”, aldus Shai Ufaz, CEO van ViAqua. “We zijn verheugd met de marktintroductie van deze technologie om tegemoet te komen aan de behoefte aan betaalbare ziekteoplossingen in de aquacultuur.”

Vooral garnalen, een van de meest geconsumeerde zeevruchten ter wereld, zijn erg vatbaar voor ziekten vanwege hun gebrek aan adaptieve immuunsystemen, en er zijn momenteel geen producten beschikbaar tegen garnalenziekten. Het eerste product van het bedrijf is een voedingssupplement om de weerstand tegen virale infecties bij garnalen te vergroten, waarbij de eerste toepassing zich richt op het White Spot Virus (WSSV), dat een jaarlijks verlies van ongeveer USD 3 miljard veroorzaakt en een vermindering van 15 procent in de wereldwijde garnalenproductie. Deze oplossing zal garnalenkwekers de broodnodige productiestabiliteit bieden en tegelijkertijd de mogelijkheid creëren om de productie per bedrijf te verhogen zonder het ziekterisico te vergroten.

“Aquacultuur is van cruciaal belang voor de duurzame aanvoer van mariene eiwitten”, zegt Kate Danaher, algemeen directeur van het Ocean and Seafood-fonds van S2G Ventures. “Met de platformtechnologie zal ViAqua verder kunnen gaan dan WSSV en tal van andere ziekten in de aquacultuur kunnen aanpakken, waarbij het nog jaren duurt voordat soortgelijke technologieën de markt bereiken.”

ViAqua produceert zijn capsuleproducten met behulp van commerciële, industriële processen en schaalt de productie op om zijn eerste product op de markt te brengen. Met plannen om de productie in India begin 2024 te starten, is het bedrijf een commercieel samenwerkingsverband aangegaan via een gezamenlijke ontwikkelings- en marketingovereenkomst met Skretting, een Nutreco-bedrijf, om het product op de markt te brengen. Terwijl ViAqua zich momenteel richt op de garnalenproductie, heeft de toedieningstechnologie talloze toepassingen in de aquacultuur en daarbuiten, die het bedrijf graag wil verkennen.

“We zijn echt enthousiast over het potentieel van ViAqua’s technologie vanwege de waarde die het ontsluit voor de planeet en de garnalenkwekers. Ziekten veroorzaken sterftecijfers tot wel 50%, wat ertoe leidt dat jaarlijks 25-30% van de garnalenkwekerijen failliet gaat. Dit is enorm onproductief en schaadt veel bestaansmiddelen,” legt Shishir Sinha, investeringsdirecteur bij Rabo Ventures, uit. “De aquacultuurspecialisten van onze bank, Gorjan Nikolik en Novel Sharma, waren onder de indruk van de baanbrekende impact van een oplossing voor een probleem dat de sector al decennialang teistert en dat een betekenisvol verschil kan maken in het leven van de kleine garnalenkwekers, die 80% van het aanbod vertegenwoordigen.”

Over ViAqua Therapeutics

ViAqua is opgericht om tegemoet te komen aan de groeiende behoefte aan effectief, specifiek en betaalbaar gezondheidsbeheer van ziekten in de aquacultuur. Een van de grootste uitdagingen bij de overgang naar een duurzame aquacultuur is de preventie en de behandeling van ziekten. ViAqua ontwikkelt een op biotechnologie gebaseerd platform voor het oraal toedienen van op nucleïnezuur gebaseerde oplossingen ter bevordering van de gezondheid bij mariene soorten.

Over S2G Ventures:

S2G Ventures, het directe investeringsteam van Builders Vision, werkt samen met ondernemers die werken aan oplossingen voor enkele van ‘s werelds grootste uitdagingen op het gebied van voedsel, landbouw, oceanen en schone energie. Wij bieden kapitaal, mentorschap en middelen met toegevoegde waarde aan bedrijven die innovatieve, commerciële oplossingen nastreven die positieve sociale, ecologische en financiële rendementen genereren. Wij bieden onze partners flexibele kapitaaloplossingen die kunnen variëren van start- en durffinanciering via groeikapitaal tot schuld- en infrastructuurfinanciering. Ga voor meer informatie over S2G naar s2gventures.com of volg ons op LinkedIn.

Over Rabo Ventures:

Rabo Ventures, onderdeel van de Rabobank, werkt samen met startende bedrijven in de hele waardeketen om hun groeiambities te ondersteunen en de vitale transities mogelijk te maken die nodig zijn in de wereldwijde voedsel- en landbouwindustrie. We investeren in geweldige managementteams die oplossingen ontwikkelen voor echte problemen, met de nadruk op het stimuleren van innovatie en duurzaamheid. Met een lokale aanwezigheid in 25 landen en ruim 100 toegewijde sectorspecialisten en onderzoekers is de Rabobank wereldleider op het gebied van Food & Agriculture banking. Als onderdeel van de captive investment-franchise van de Rabobank, Rabo Investments, maken we gebruik van het platform, de kennis en het netwerk van de banken om uw bedrijf te ondersteunen en te laten groeien en tegelijkertijd de van belang zijnde transities te versnellen.

Mediacontact:
Ally Dunne
Ally.Dunne@zenogroup.com

SOURCE ViAqua Therapeutics

NEW YORK, Sept. 5, 2023 — The Shipyard, advised by JEGI CLARITY, has received an investment from Alaris Equity Partners.

Founded in 2013 and headquartered in Columbus, OH, The Shipyard is an integrated marketing agency renowned for “Engineering Brand Love” by uniquely combining data science with integrated media, creative, and analytical processes to discover and engage all relevant audience segments via omnichannel marketing campaigns, driving marketing outcomes and accelerating brand growth. The Company’s audience discovery approach, “No Customer Left Behind”, is supported by a proprietary data intelligence engine, The Helm, combined with a full-suite of end to-end, agency of record marketing solutions to drive measurable and sustainable results for brands. The Shipyard has developed vertical expertise across highly attractive sectors, including Travel & Tourism, Financial & Professional Services, Energy & Sustainability, and Consumer Packaged Goods/Retail, with significant runway and ongoing initiatives to further penetrate each.

This new partnership will enable The Shipyard to strengthen their current offerings and expand their presence in the market. Rick Milenthal, Chairman & CEO of The Shipyard said, “The Alaris investment model is perfect for a growing successful company like The Shipyard. They back our team and fuel our growth, fully empowering our management team to do what is best for our people and our clients.”

About JEGI CLARITY
JEGI CLARITY is a pre-eminent M&A advisory firm for the media, marketing, information and technology industries. With a global reach from New York, London, Boston, Sydney and San Francisco, we have closed more than 800 transactions during our 35+ year history. For more information, visit www.jegiclarity.com.

Contact: Kelsey Kovachik, Vice President of Marketing
+1 212 754 0710 | [email protected] | www.jegiclarity.com/

SOURCE JEGI CLARITY

The platform allows companies to spot and react to current consumer trends, by providing AI-generated product attributes from titles, descriptions, ingredients, reviews, and more

NEW YORK, Sept. 4, 2023 — Harmonya, a software company transforming CPG and retail with AI-powered product data, announced today their $20M Series A, bringing their total funding to $25M. The round was led by Bright Pixel Capital with the participation of existing investor Team8, as well as Arc Investors, J Ventures, Silicon Road Ventures, Allen & Company, LiveRamp Ventures, and Susa Ventures. The funds will be used to further develop Harmonya’s proprietary generative AI technology, enhance its suite of tools, and scale its go-to-market operations.

The current product data infrastructure used by major retailers and consumer packaged goods companies relies on outdated, static data models that lack a granular understanding of individual products. “When a new consumer trend emerges, like Sustainability or Wellness, CPGs and retailers need to go over all of their existing products after the fact and manually add attributes to each,” said Cem Kent, CEO and Co-Founder of Harmonya. “This limits their ability to quickly identify and respond to emerging consumer preferences, power accurate demand forecasting, and create tailored shopping experiences.”

Harmonya offers an AI-powered product data enrichment, categorization, and insights platform for retailers and brands. The solution harnesses the power of cutting-edge generative AI and large language models to dynamically surface product attributes from a wide range of sources. Harmonya’s platform helps its users identify consumer drivers of market performance, uncover category insights, optimize assortment and merchandising, guide innovation, and automate the process of product coding.

“The CPG and retail industries are vast and ever-changing, presenting countless opportunities for innovation–especially in the area of product data, where current approaches and technology don’t meet the standards of modern data-driven organizations,” said Francisco Nunes of Bright Pixel Capital. “Harmonya’s groundbreaking platform positions the company as a key player in unlocking the untapped potential within these industries, bringing them closer to how consumers perceive and experience products.”

Harmonya’s customers include four of the top ten global CPGs as well as some of the largest US retailers. The company has grown its customer base significantly in the first half of the year, serving data teams in HQ as well as customer teams working directly with merchants and buyers. Harmonya’s proprietary technology ingests information from millions of online product listings and creates unique tags from titles, descriptions, ingredients, consumer reviews, and more, and relies on a proprietary large-language model trained on their retail-specific data repository.

“Bright Pixel Capital’s deep understanding of retail and CPG technology further validates the transformative potential of the Harmonya platform,” said Cem Kent. “This investment will help us further our mission to bridge the gap between legacy product data, which lacks descriptive and diagnostic power and limits what organizations can do, and the modern need for a dynamic product language to power more impactful analytics and decision-making.”

“We’ve been looking closely at potential uses of data technologies and data infrastructure,” said Yuval Shachar, Managing Partner and Executive Chairman of Team8. “It was clear to us that there’s a market need for a company to disrupt the space in the retail industry and unlock tremendous value by adapting product data for the AI era. Harmonya is doing just that, and we are glad to partner with Harmonya’s great team, as part of Team8’s unique company-building model, to help retailers and CPGs gain a consumer-centric perspective in a modern, AI-powered fashion.”

About Harmonya

Harmonya is the all-in-one AI-powered product data enrichment, categorization, and insights platform for retailers and brands. Based in New York with an office in Tel Aviv, the company builds revolutionary technologies and tools to help its customers realize their full potential through deeper product understanding. Harmonya transforms static, commoditized product data into a dynamic resource to enrich, categorize, and draw insights from products and help Fortune 500 CPGs and retailers grow their businesses.

To learn more, please visit: www.harmonya.com.

About Bright Pixel Capital (formerly Sonae IM)

Bright Pixel Capital, formerly known as Sonae IM, is the technology investment arm of the multinational group Sonae. With a special focus on cybersecurity, digital infrastructure, and retail technologies, it has a portfolio of more than 50 companies, from early to growth stages. Bright Pixel Capital acts as a partner that brings specialized know-how, a global footprint, and a wealth of experience in helping companies from early stage to IPO.

Find out more at brpx.com.

About Team8

Team8 Group is a global Company-Building and Venture Capital group that creates and invests in companies focusing on Cybersecurity, Data & AI, Fintech, and Digital Health.

Team8’s signature foundry model is designed to identify meaningful problems, create theses on potential solutions, and build innovative companies that tackle these challenges.

Team8 foundry model leverages an in-house multi-disciplinary team of more than 90 company-builders located in Tel Aviv and New York, together with dedicated communities of global C-level executives and thought leaders grouped as Team8 domain-focused villages.

Visit www.team8.vc to learn more.

SOURCE Harmonya

NEW YORK, Sept. 5, 2023 — Madison International Realty, a leading liquidity provider to real estate investors worldwide, announced the final closing of Madison International Real Estate Liquidity Fund VIII, its latest commingled investment vehicle, with $1.7 billion of equity commitments, including side cars, co-investment vehicles and general partner commitments.

“In the midst of a volatile market and an extremely challenging fundraising climate, investors have continued to demonstrate confidence in Madison’s differentiated strategy,” said Ronald M. Dickerman, Madison International Realty Founder and President. “We are gratified with the robust support we have received from both returning and new investors for Madison VIII’s capital raise.  Madison’s direct secondary investment strategy is targeted to be counter-cyclical, allowing us to leverage opportunities in rapidly changing economic conditions.

“Given our position as a liquidity provider, we have been able to make well-timed investments and increase our allocations to tech enabled, growth oriented real estate asset classes,” Dickerman said.

Madison International Realty focuses on the acquisition of ownership stakes in prime properties and portfolios in demographically compelling geographies of the US, UK, and Europe. Madison VIII is invested or specified in several diversified investments in the multi-family, industrial, cold storage, single family rental, life science, and data center sectors across the US, UK, and Europe.

Madison VIII investors include endowments, foundations, public and private pension funds, sovereign wealth funds, family offices, insurance companies and high net worth individuals in the US, Europe, Asia, the Middle East, and Australia.

About Madison International Realty
Madison International Realty (www.madisonint.com) is a leading liquidity provider to real estate investors worldwide. Madison provides equity capital for real estate owners and investors seeking to monetize embedded equity, replace capital partners seeking an exit or to recapitalize balance sheets. The firm provides equity for recapitalizations, partner buyouts and capital infusions; and acquires joint venture, limited partner and co-investment interests as principals. In addition, Madison provides strategic growth capital to established, middle-market real estate operating platforms, seeking to accelerate their growth and investment programs. Madison has offices in New York, Los Angeles, London, Luxembourg, Amsterdam, and Frankfurt, where the firm operates under the name of Madison International Realty GmbH.

SOURCE Madison International Realty

LISBON, Portugal, Sept. 5, 2023 — APEX, an athlete-driven investment company, today announced the launch of its new €50 million Elite Performance Fund. This investment vehicle is poised to reshape the landscape of sports, media, and entertainment by channeling the expertise and vision of world-renowned athletes such as Formula 1 sensations Lando Norris and Carlos Sainz and FIFA World Cup and UEFA Champions League winner Raphaël Varane. 

The fund’s core philosophy revolves around fostering innovative solutions that redefine the boundaries of the sports, media, and entertainment industries. Investors gain privileged access to a diverse portfolio meticulously managed by APEX’s team of experts known for their credibility and ability to find the right opportunities in the market.

Also joining the list of star investors are, among others, F1’s Valtteri Bottas, international footballers Christian Eriksen and Daley Blind and surfer Kanoa Igarashi.

APEX CEO António Caçorino said, “This fund fuses the drive, dedication, and performance mindset of athletes with forward-looking investment strategies. Unlike typical investors, our roots, experience, and insights come directly from the sports world. Athletes aren’t just our capital sources; they’re our partners.”

Lando Norris, McLaren Formula 1 driver: “As an athlete, I’m always focused on performing at my best, so it’s going to be exciting to apply this perspective when I’m working alongside APEX to drive innovation in the sports, media and entertainment space.”

Carlos Sainz, Ferrari F1 driver: “Being deeply involved in sports has given me a unique perspective on its landscape. With APEX’s guidance, I’m tapping into that insight to discover exciting investment opportunities. It’s not just about capital for me; it’s about strategically positioning myself as a genuine contributor in the sports investment world.”

Raphaël Varane, Manchester United and France international: “I have been investing in startups for some time now. Gaining access to the right opportunities is paramount. By joining APEX, I will not only be able to access the right opportunities, on top of that I can share my investment experiences with other athletes and learn from theirs. A powerful and exciting combination.”

Kanoa Igarashi, WSL Surfer, Olympic medalist: “By partnering with APEX, I can invest and collaborate with companies that have the potential to shape the future of sports. I believe that through my experiences as a professional athlete, I can add unique insights as an investor.”

The Portuguese investment company has already invested in other elite sports ventures such as TMRW SPORTS’ Tiger Woods and Rory McIlroy (https://tmrwsportsgroup.com/tmrw-sports-adds-all-star-investors).

SOURCE APEX

SINGAPORE and MUMBAI, India, Sept. 5, 2023 — IndoSpace, the largest investor, developer, and operator of grade A industrial and logistics real estate in India, is pleased to announce the successful completion of its second round of fundraising for IndoSpace Logistics Parks IV (“ILP IV”), securing an additional USD 150 million in investment. The round was led by the Qatar Investment Authority (“QIA”), and Grosvenor’s Diversified Property Investments business.

Following the initial close of USD 243 million, this second round of funding increases the fund size to USD 393 million and demonstrates the continued confidence and support from leading global investors in IndoSpace’s advanced approach to industrial real estate development in India.

QIA and Grosvenor’s participation in this round reflects the attractive opportunity to develop modern grade A industrial and logistic parks in the world’s fastest growing large economy. The funds raised in this round will continue to advance IndoSpace’s mission of developing state-of-the-art industrial and logistics parks across the top 8 markets in India.

With a strong focus on sustainability and modern design, IndoSpace provides world-class infrastructure and tailored solutions to meet the evolving needs of businesses operating in the e-commerce, manufacturing, retail, and logistics sectors.

IndoSpace has a proven track record of leveraging its deep understanding of market dynamics and strong industry relationships to deliver returns to investors while also driving economic growth and job creation in India.

ILP IV will add an additional 25-30 million square feet to the IndoSpace portfolio, furthering IndoSpace’s leading position in the Indian market. ILP IV will focus on India’s largest logistics real estate markets: Ahmedabad, Bangalore, Chennai, Delhi, Hyderabad, Kolkata, Mumbai, and Pune. The establishment of ILP IV follows on from the first three development funds, which have a combined total of 58 million square feet of modern logistics real estate in India completed and under development.

About Qatar Investment Authority

Qatar Investment Authority (“QIA”) is the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term perspective that can deliver sustainable returns and contribute to the prosperity of the State of Qatar.

About Grosvenor Diversified Property Investments

Grosvenor Diversified Property Investments backs local partners globally, who share Grosvenor’s core values, have specialist expertise and a demonstrable investment track record. The team sits within the wider Grosvenor business, an international organisation whose activities span urban property, food and agtech, rural estate management and support for philanthropic initiatives. By investing Grosvenor’s own capital alongside local partners who have a clear understanding of the changing demands of real estate in their markets, the business aims to generate strong commercial results, while advancing Grosvenor’s social and environmental ambitions. Since its first partnership in 2012, the team has successfully backed aligned, specialist, local management teams across five continents and in a broad range of sectors including industrial/ logistics, student accommodation, life sciences, healthcare, housing, and offices. Find out more here.

About IndoSpace

IndoSpace (www.indospace.in) is the largest investor, developer, and operator of grade A industrial and logistics real estate in India. IndoSpace has the largest national network of 51 logistics parks with 58 million square feet delivered/under development across 11 cities. With India’s largest and most experienced industrial real estate team, IndoSpace continues to lead the development of key logistics infrastructure for India’s economic growth. For more information, visit www.indospace.in and follow us on LinkedIn, Twitter, and Facebook.

Photo: https://mma.prnewswire.com/media/2201490/IndoSpace_Park.jpg

SOURCE IndoSpace

COPENHAGEN, Denmark, Sept. 5, 2023 — BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that six companies are to receive additional financial support through its Venture House program, created to further support former Venture Lab companies through their next phase of growth.

The Venture House program provides exclusive follow-on funding in the form of a founder-friendly convertible loan of EUR 1.3M to selected companies that have already participated in the 12-month Venture Lab program created to support business acceleration, scientific and team development. As part of the Venture House program, companies will also take advantage of BII’s extensive network to help establish a strong board, chairman and key scientific advisors. This is the third cohort of companies to be accepted into the Venture House program since its launch in August 2022.

To support product innovation and ecosystem growth, the program consists of four executive sprints, each focused on a key development area to help mature the project and ultimately attract further funding. The first sprint focuses on helping companies develop an operational plan, while the following sprints provide training and support in fundraising, partnership, and leadership.

Bobby Soni, Chief Business Officer at BioInnovation Institute, said: “These six companies have shown promise during their time in the Venture Lab program and collectively align with BII’s focus on providing solutions to benefit people and society. On behalf of the team at BII, we look forward to continuing to work alongside these innovative companies as they mature and attract funding.”

All six companies have partaken in BII’s Venture Lab program that supports business acceleration, scientific development and team development in which each company received a risk-free convertible loan of EUR 500,000 plus access to labs and offices at the BII’s entrepreneurial ecosystem in the center of Copenhagen. Thus, after entering the Venture House program they have received in total EUR 1.8M. The new companies the BII has accepted into the Venture House program are:

• TriptoBIO is developing a high-value plant compound production platform focused on triptolide to liberate the world from rat poison.
• Agrobiomics develops transformative natural solutions, with a vision of securing sustainable food supply, that make agriculture resilient to climate change. The Company’s solutions are affordable and highly potent, thereby enabling growers globally to increase yields of crops affected by abiotic stress such as salinity and drought.
• MATR Foods is producing delicious new plant food from the side streams of the current food industry.
• HHC Medical is building a platform technology for non-viral delivery of genetic therapies. The approach will enable genetic therapies to be delivered very specifically to a target volume anywhere in the body.
• Solid Therapeutics is developing novel cancer therapeutics with dual performance targeting cancer cells and immune cells to treat solid tumors.
• FimmCyte is dedicated to developing tailored women’s health therapeutics. FimmCyte’s lead program, FMC2, is a first-in-class disease-modifying treatment for endometriosis. FimmCyte is jointly supported by BII and Ferring Pharmaceuticals through a strategic collaboration.

Since its inception in 2018, BII has supported 87 start-ups and projects with EUR 85 million alongside the venture capital, industry and business expertise it provides to help them accelerate to the next level. In total, BII’s start-ups have raised over EUR 424 million in external funding from both local and international investors. Recent company successes include Embark Laboratories, Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical.

Read more about the Venture House program here.

About the BioInnovation Institute Foundation:

At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation for the benefit of people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio, Venture Lab and Venture House, to support life science start-ups with knowledge, network, infrastructure and funding of up to 3M EUR per projects and 1,8 M EUR per start-up. With our expertise, network, funding, and infrastructure, we empower startups to succeed and believe in the transformative power of life science innovation. Read more on www.bioinnovationinstitute.com 

SOURCE BioInnovation Institute